UPDATE – PharmaEssentia has corrected the press release issued 6 January about the Phase III results for Besremi in essential thrombocytopenia to note the incidence of two treatment-related serious adverse events in the Besremi arm; the previous press release reported zero TRSAEs. Scrip has revised this article to include the new data and confirmed the company’s view that Besremi has a relatively better safety profile than anagrelide.
With Phase III Success, PharmaEssentia To Seek Besremi Label Expansion (Update)
Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.
More from Clinical Trials
More from Therapy Areas
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.